Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy (NCT04638920), a registered phase not stated study. The primary outcome is Change in Exhaled Breath Metabolites.

2. Clinical Question

3. Trial Design

TripleEX is a completed registry study titled “Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy.” The listed sponsor is Malcolm Kohler. The recorded start date is 2020-11-16, and the primary completion date is 2024-04-30. The enrollment is 35.

The listed arm is Exacerbators, described as patients with acute COPD exacerbation under triple inhalation therapy. The intervention is recorded as “No intervention.” The registry record does not describe a randomized allocation or a like-for-like control comparison; allocation is not stated. The study is therefore described by its breath-measurement objective, not as a comparison of treatment assignments.

The brief summary describes determining molecular breath patterns during a COPD exacerbation and 8 weeks afterward, and assessing their association or correlation with clinical outcomes and treatment. The primary endpoint focuses on the count of exhaled-breath features whose intensity changes between those measurements. The record also lists secondary outcomes concerning symptoms, inflammation, causative agents, and treatment. It records 5 outcome measures and no analyses.

Breath data for two participants were not analyzable because of technical problems. The registry record does not explain whether or how those data were handled in the endpoint analysis, nor does it report a final analysis population. A completed status indicates the trial record is marked completed; it does not by itself supply the missing endpoint estimates or analysis details.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Exhaled breath data of two participants were not analazable due to technical problems.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Data of 28 participants were included in the final analysis as five patients withdrew their participation and the main outcome (breath analysis) of two participants was not analyzable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Exhaled Breath Metabolites, measured over twice during 8 weeks.

The primary endpoint is the number of exhaled-breath features or metabolites that show a change in intensity between measurements during a COPD exacerbation and after the exacerbation, 8 weeks later. The features are measured with a mass spectrometer. The record defines the change for each detected feature as intensity during the exacerbation minus intensity after the exacerbation. The feature unit is mass over charge ratio, while the endpoint itself is a count of features.

As a general statistical idea, a count can summarize how many measured features meet a stated criterion, rather than the size or direction of change for each feature. That can make a complex molecular profile easier to describe. However, the registry record does not state the threshold or rule used to decide that a feature “shows a change.” It also does not report the numerical count, the feature-level estimates, or uncertainty around the endpoint. Those omissions limit interpretation of what the count represents and how precisely it was estimated.

The stated contrast is temporal: during the exacerbation versus after 8 weeks. It is not described as a treatment effect against a concurrent control group. The numerical primary endpoint result is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record describes a count-based primary endpoint derived from mass-spectrometry measurements. The primary endpoint is the number of detected exhaled-breath features showing an intensity change between the exacerbation measurement and measurement after 8 weeks. The stated feature-level change is intensity during the exacerbation minus intensity after the exacerbation. The statistical methods used to turn those measurements into a reported endpoint are not reported in the registry record.

What does a count endpoint represent?

As general statistical context, a count records how many items satisfy a defined condition. Here, the items are detected breath features, and the condition is described as showing a change in intensity. A count can convey the breadth of a profile change, but it does not by itself convey the size of each feature’s change, whether the changes are positive or negative, or whether a change is biologically meaningful. Those questions require feature-level results and a clear definition of the rule for classifying a feature as changed. That classification rule is not reported in the registry record.

Count outcomes are often analyzed with methods suited to nonnegative integer data. Some methods assume that the variability in counts follows a specified relationship to the average count. If the observed variability is greater than that assumption allows, over-dispersion may matter: standard errors can be too small under an inadequate model, making uncertainty appear narrower than it should. This is general methodological context, not a finding about this trial. The registry record does not report a count model, a dispersion estimate, or a check of model assumptions.

How should the time contrast be understood?

The endpoint definition uses a difference in intensity between measurements during an exacerbation and after 8 weeks. In general, a within-person temporal contrast can describe how measurements vary over time in the observed participants. It does not by itself identify why a change occurred. A control group or other design features may help distinguish the effect of time from other explanations, but the record does not describe a control comparison or allocation procedure. The listed arm is Exacerbators, and the intervention is “No intervention.”

The subtraction order is specified: during-exacerbation intensity minus after-exacerbation intensity. Under that definition, a positive feature-level difference would indicate a higher during-exacerbation intensity, while a negative difference would indicate a lower one. This is an explanation of the stated arithmetic, not a claim that either direction occurred. Numerical feature-level results are not reported in the registry record.

What information would support precision?

As general statistical context, an estimate describes the observed quantity, while a standard error or confidence interval describes its sampling uncertainty under a specified analysis. For a count derived from many measured features, uncertainty can also depend on how features were selected, how missing measurements were handled, and whether repeated observations or correlations among features were accounted for. The registry record does not report an estimate, confidence interval, standard error, or analysis method for the primary endpoint.

Confidence intervals are not guarantees that a parameter lies within a particular interval. They communicate uncertainty conditional on the statistical model and the data used. A narrow interval can indicate greater precision under that model, while a wide interval indicates greater uncertainty. Since no interval is reported, the precision of the primary endpoint cannot be assessed from the registry record.

How does multiplicity arise in molecular measurements?

General statistical context is especially relevant when many features are measured. Testing or screening many features creates multiple opportunities to flag a result as noteworthy by chance. Methods for controlling multiplicity can limit particular kinds of false-positive findings, but the appropriate method depends on the analysis goal. The registry record does not state how many feature-level tests were planned, whether features were screened individually, or whether any multiplicity adjustment was used.

The record lists 5 outcome measures and 0 analyses. It does not provide outcome-specific results or identify a statistical analysis plan. Thus, it is not possible to determine from the record whether the intended analyses were prespecified, how correlations with clinical outcomes were evaluated, or how uncertainty was handled across outcomes.

What do the planning assumptions mean?

The sample-size planning illustration is described as using the observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It considers the effect to detect as a stated fraction of the observed effect. These are planning assumptions for an illustration, not evidence that the trial was designed or analyzed using those assumptions. The registry record does not report the trial’s own sample-size justification.

Any sample-size figures generated from an observed effect are planning illustrations, not observed power. They describe how a future design might be planned under stated assumptions; they do not measure the probability that the completed trial detected a real effect. The record identifies no randomized comparison, and its listed arm is Exacerbators. The assumptions about equal allocation between two arms therefore should not be mistaken for a description of the reported trial design.

For time-to-event outcomes, the planning note refers to a total event count; for other outcomes, it refers to participants per arm. Those conventions explain the form of a planning calculation in general. The record does not give a time-to-event primary endpoint, and no planning result is reported in the registry record. The endpoint results and the trial’s statistical analysis plan are also not reported.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 5 outcome measures and 0 analyses. It identifies the primary endpoint as a count of breath features whose intensity changes between exacerbation and after 8 weeks, and lists secondary outcomes concerning symptoms, inflammation, causative agents, and treatment. Numerical results for these outcomes are not reported in the registry record.

Multiplicity is a concern in general when several outcomes or many molecular features are examined. The chance of obtaining at least one apparently notable result can increase when many tests are conducted. Statistical approaches can address multiplicity, but the choice depends on which outcomes are confirmatory and how the analyses are organized. Whether any multiplicity adjustment was planned or applied is not reported in the registry record. The record also does not give a list of feature-level tests or identify which findings, if any, were designated as primary within the secondary outcomes.

Breath data for two participants were not analyzable because of technical problems. The registry record does not say whether those observations were excluded from all analyses, whether any values were imputed, or how the unusable data affected the analysis population. It also does not report other missing-data handling rules or an analysis population definition. These details are important because they affect what data support an estimate and how broadly it can be interpreted.

The statistical analysis plan, including any prespecified model, missing-data approach, and multiplicity procedure, is not reported in the registry record. No endpoint estimate or uncertainty measure is reported.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry safety figures list 35 participants at risk for serious adverse events and 0 affected. For other adverse events, the record also lists 35 at risk and 0 affected. The reported number of deaths is 0, and no top serious-event terms are listed.

These figures describe what is recorded in the registry; they are not a detailed account of event surveillance. The record does not provide event descriptions, observation periods for safety collection, severity grades, or information about how events were collected and attributed. It also does not report a separate safety analysis. A zero count in the posted record should therefore be read as no affected participants reported in those categories, not as proof that no events occurred under every possible definition or outside the recorded observation process.

The safety counts do not establish a comparison between treatments. The listed intervention is “No intervention,” and the registry does not describe a randomized control group. These figures should be interpreted as descriptive registry counts for the listed Exacerbators arm, not as evidence about comparative safety or treatment effects.

12. What the Result Does, and Does Not, Mean

The registry record establishes the study’s stated measurement question: whether the intensity of detected breath features differs between measurement during a COPD exacerbation and measurement after 8 weeks, and how many features meet the change criterion. It identifies the measurement technology and defines the direction of the feature-level subtraction. It also records that breath data for two participants were not analyzable because of technical problems.

The record does not report the numerical primary endpoint result, feature-level estimates, or uncertainty. It therefore does not show how many features changed, how large any changes were, or how precisely those changes were estimated. It also does not report numerical results for the secondary outcomes concerning symptoms, inflammation, causative agents, or treatment. The stated interest in correlations and associations is an objective, not a reported finding.

The study is not described as a randomized treatment comparison. The listed intervention is “No intervention,” the arm is Exacerbators, and allocation is not stated. A temporal difference in breath measurements, if observed, would describe change across the measurement times; without an appropriate comparison and reported analysis, it would not establish that a particular treatment caused that change.

In general, a measured change is not automatically a clinically meaningful change. Interpretation depends on the measurement’s reliability, the criterion used to label a feature as changed, the magnitude and uncertainty of the estimated change, and the relationship to clinical outcomes. Those details are not reported in the registry record. The completed status and recorded enrollment do not substitute for endpoint results or an analysis description.

The registry record supports a description of the question and measurement plan, along with the posted safety counts. It does not support a quantitative conclusion about breath-metabolite findings or their clinical significance.

13. Why This Trial Matters Statistically

This trial raises a useful statistical problem: how to summarize a molecular breath profile that may contain many measured features. Its primary endpoint is a count of features with changed intensity across a temporal contrast. Such a count can be easier to communicate than a long list of measurements, but it depends on a clearly specified rule for deciding which features count as changed. That rule is not reported in the registry record.

The measurement setting also illustrates the distinction between describing change and attributing its cause. The endpoint compares measurements during an exacerbation with measurements after 8 weeks. As a general principle, a time contrast can characterize what happened across those observations, but it does not on its own separate time effects from other influences. The registry record does not describe a randomized control comparison.

Many-feature measurements raise questions about multiplicity, correlation among features, and uncertainty. General statistical methods can address these issues, but interpretation requires knowing which analyses were planned and how results were selected and adjusted. The record lists 5 outcome measures and 0 analyses, and does not report an analysis plan, feature-level results, or uncertainty estimates.

The record also notes that breath data for two participants could not be analyzed because of technical problems. This makes data handling and analysis-population definitions important for understanding how much information contributes to an estimate. Those details are not reported in the registry record. The trial is statistically informative as a measurement-focused question, while the absence of numerical endpoint results limits what can be concluded from the posted record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation of the registry information is that it does not report the numerical primary endpoint result. No feature-level results, estimate of the count, or uncertainty measure is given. The criterion for deciding that a feature “shows a change” is also not reported, so the operational meaning of the endpoint cannot be fully assessed.

The brief summary describes assessing associations between breath patterns and clinical outcomes and treatment, but numerical results for the listed secondary outcomes are not reported. The record lists 5 outcome measures and 0 analyses. It does not provide a statistical analysis plan, details of feature selection, a model specification, or a multiplicity procedure.

Two participants’ breath data were not analyzable because of technical problems. The record does not describe the handling of these data, whether other observations were missing, or the final analysis population. It does not report measurement quality checks, repeatability, or the extent to which technical problems affected particular features.

The design information also limits causal interpretation. The registry lists “No intervention” and one described arm, Exacerbators; allocation is not stated, and no like-for-like control comparison is described. The temporal contrast is not, by itself, a treatment comparison. The registry record does not report the sample-size justification or the statistical plan used for analysis. These omissions do not establish that a procedure was absent; they mean it is not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy — NCT04638920.
• Registry record last updated 2025-04-02; status last verified 2025-03.
• Results first posted 2025-04-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

TripleEX is a completed study of molecular breath patterns in patients with acute COPD exacerbation under triple inhalation therapy. The registry lists enrollment of 35, a start date of 2020-11-16, and a primary completion date of 2024-04-30. The listed intervention is “No intervention,” and the described arm is Exacerbators.

The primary endpoint is the number of exhaled-breath features showing an intensity change between the exacerbation measurement and measurement after 8 weeks, measured by mass spectrometry. Breath data for two participants were not analyzable because of technical problems. The numerical primary result, statistical analysis plan, and analysis population are not reported in the registry record.

The safety record lists 0 participants affected by serious adverse events, 0 affected by other adverse events, and 0 deaths. These are descriptive registry counts, not a randomized treatment comparison.